Clinical trials: Hepatic Fibrosis
Liver Cirrhosis
Long-term Efficacy and Safety of LSD Versus TIPS for Cirrhotic Portal Hypertension Bleeding and Hypersplenism
This study aims to compare two treatments for cirrhotic portal hypertension with acute esophagogastric variceal bleeding and hypersplenism: laparoscopic splenectomy and azygoportal disconnection (LSD) and transjugular…
- Trial name
- LSD、TIPS (NCT07490405)
- Testing
- LSD, TIPS
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Northern Jiangsu People's Hospital
COVID-19, Chronic Liver Failure
Evaluation of Long Haul COVID-19 and Vaccine Immunogenicity in Patients With Liver Disease
The project is essential to understand the impact of the COVID-19 pandemic in patients with Chronic Liver Disease (CLD). The impact has been felt due to direct risk of COVID infection in self, or in caregivers, lack of access to…
- Conditions
- COVID-19, Chronic Liver Failure, Cirrhosis, Liver, Portal Hypertension
- Trial name
- EvaLongCovid (NCT05107271)
- Testing
- COVID-19 serosurvey
- Where
- India
- Volunteers
- 252 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Cirrhosis
Transjugular Intrahepatic Portosystemic Shunt With 8- or 10-mm Covered Stents
Coated stents with different diameters are presently commercially available, but clinical studies on the assessment of the best stent diameter for a better clinical efficacy, a reduced number of complications, and an effective…
- Trial name
- NCT00401895
- Testing
- TIPS created with 8 or 10 mm covered stent
- Where
- Italy
- Volunteers
- 44 people
- Sponsor
- University of Roma La Sapienza
Liver Fibrosis
Study of Hydroxynidone Capsules in Patients With Hepatic Impairment and Matched Healthy Controls
This trial adopts a single-center, single-dose, open-label, non-randomized, parallel-controlled design. It will be conducted in participants with varying degrees of hepatic impairment, as well as in participants with normal…
- Trial name
- NCT07394309
- Testing
- Hydronidone capsules
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Beijing Continent Pharmaceutical Co, Ltd.
Cirrhosis, Liver, End Stage Liver DIsease
Testing LiverWatch, a Home-Based Remote-Monitoring Intervention for Advanced Liver Disease
Remote healthcare monitoring for cirrhosis has shown promise in overcoming barriers to accessing specialty care, improving healthcare quality, and reducing mortality.
- Conditions
- Cirrhosis, Liver, End Stage Liver DIsease, Symptoms and Signs, Physical Inactivity
- Trial name
- NCT06136221
- Testing
- LiverWatch Intervention
- Where
- 2 sites in United States
- Volunteers
- 110 people
- Sponsor
- University of Pennsylvania
Metabolic Dysfunction-Associated Steatotic Liver Disease
Impact of Live Streaming Exercise on Liver Health in MASLD Pregnant Women
Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) is a clinical and pathological syndrome characterized primarily by excessive intracellular fat accumulation in the liver, excluding alcohol-related and other…
- Trial name
- NCT06682663
- Testing
- Live Streaming Exercise
- Where
- China
- Volunteers
- 220 people
- Sponsor
- Peking University
Liver Fibrosis
Rapid Breath-hold Quantitative Macromolecular Proton Fraction Imaging for Liver Fibrosis
Chronic liver disease is a major health problem worldwide. Liver fibrosis is a key feature in most chronic liver diseases. When identified early, liver fibrosis may be reversible.
- Trial name
- NCT04429100
- Testing
- Magnetic Resonance Imaging
- Where
- Hong Kong
- Volunteers
- 200 people
- Sponsor
- Chinese University of Hong Kong
Liver Fibrosis, Hepatic Fibrosis
A Trial of IDN-6556 in Post Orthotopic Liver Transplant for Chronic HCV
This is a double-blind, multicenter study involving patients with chronic HCV infection who had a liver transplantation; developed HCV-related liver fibrosis and/or incomplete cirrhosis; achieved a sustained virologic response…
- Conditions
- Liver Fibrosis, Hepatic Fibrosis, Liver Cirrhosis, Hepatic Cirrhosis
- Trial name
- POLT-HCV-SVR (NCT02138253)
- Testing
- IDN-6556
- Where
- 35 sites in United States
- Volunteers
- 64 people
- Sponsor
- Conatus Pharmaceuticals Inc.
Hepatic Encephalopathy
Effects of Proteins in Patients With Cirrhosis and Prior Hepatic Encephalopathy
The purpose of this study is to compare a normal-protein diet containing branched-chain amino acids to a low-protein diet in patients with non-terminal cirrhosis (MELD < 25) who have developed an episode of hepatic encephalopathy…
- Trial name
- NCT00955500
- Testing
- Branched-chain amino acids, Maltodextrin
- Where
- 3 sites in Spain
- Volunteers
- 116 people
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
Chronic Hepatitis C, Cirrhosis
Transient Elastography to Assess Liver Fibrosis and Portal Hypertension in HCV Cirrhotic Patients Treated With New Antiviral Drugs (SPLEEN-C)
The purpose of this study is to evaluate the effects of sustained virological response in liver and spleen stiffness in patients with HCV compensated advanced chronic liver disease treated with new all oral antiviral drugs in…
- Conditions
- Chronic Hepatitis C, Cirrhosis, Portal Hypertension
- Trial name
- SPLEEN-C (NCT02439567)
- Testing
- Fibroscan: Liver and Spleen elastography
- Where
- Spain
- Volunteers
- 41 people
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
Chronic Hepatitis B, Chronic Hepatitis C
Assessment of Liver FIBROsis by Real-time Tissue ELASTography in Chronic Liver Disease
This is a multi-center cross-sectional study in which the Real-time Tissue Elastography® measurements will be collected prospectively from patients with chronic hepatitis B or C virus presenting for liver biopsy.
- Trial name
- FIBROELAST (NCT01360879)
- Where
- Japan
- Volunteers
- 500 people
- Sponsor
- Kindai University
Cirrhosis
Multicenter Prospective Randomized Trial of the Effect of Rivaroxaban on Survival and Development of Complications of Portal Hypertension in Patients With Cirrhosis
The main objective of the study will determine if patients with liver cirrhosis, anticoagulation free survival improves hypertension decompensation portal and / or transplantation without serious side effects.
- Trial name
- CIRROXABAN (NCT02643212)
- Testing
- Rivaroxaban
- Where
- 14 sites in Spain
- Volunteers
- 160 people
- Sponsor
- David Garcia Cinca
Portal Hypertension, Chronic Liver Disease (CLD)
EUS-guided Portal Pressure Gradient (PPG) Measurement: a Potential Alternative to the Traditional HVPG
The goal of this investigator-initiated, single-arm, prospective study is to evaluate the accuracy, safety, and feasibility of endoscopic ultrasound-guided portal pressure gradient (EUS-PPG) measurement as a potential alternative…
- Conditions
- Portal Hypertension, Chronic Liver Disease (CLD), Cirrhosis
- Trial name
- EUS-PPG (NCT06863012)
- Testing
- Endoscopic Ultrasound-Guided Portal Pressure Gradient (EUS-PPG) Measurement, Hepatic Venous Pressure Gradient (HVPG) Measurement
- Where
- Spain
- Volunteers
- 20 people
- Sponsor
- Fundacio Privada Mon Clinic Barcelona
Colorectal Adenoma, Colorectal Neoplasm
ObeSity Related Colorectal Adenoma Risk
In the UK, around 1 in 16 men and 1 in 20 women will develop bowel cancer at some point in their lives. Most bowel cancers happen when a type of growth in the bowel called an adenoma eventually becomes cancerous.
- Conditions
- Colorectal Adenoma, Colorectal Neoplasm, Colorectal Cancer, Obesity
- Trial name
- OSCAR (NCT03663062)
- Testing
- Colonoscopy
- Where
- 12 sites in United Kingdom
- Volunteers
- 1,430 people
- Sponsor
- South Tyneside and Sunderland NHS Foundation Trust
Hepatitis C, Chronic
Evaluation of Irbesartan on Hepatic Fibrosis in Chronic Hepatitis C
The purpose of this study is to examine the efficacy of irbesartan on the progression of liver fibrosis in adult patients with chronic hepatitis C. The expected total enrollment is 200 patients.
- Trial name
- Fibrosar (NCT00265642)
- Testing
- Irbesartan
- Where
- France
- Volunteers
- 166 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Liver Cirrhosis, Portal Hypertension.
Hemodynamic Effect of Simvastatin With Beta Blockers in Clinical Portal Hypertension
In the genesis and maintenance of PH associated with liver cirrhosis are two mechanisms that act synergistically. The first is an increase in hepatic vascular resistance, due in part to the disruption of liver structure inherent…
- Trial name
- SIMBETA (NCT01282385)
- Testing
- Simvastatin
- Where
- Spain
- Volunteers
- 60 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Hepatic Impairment, Cirrhosis
Hepatic Impairment With Cirrhosis Due to Cholestatic Liver Disease
A Phase 1, Open-label Extension Groups Study in Subjects having Hepatic Impairment with Cirrhosis due to Cholestatic Liver Disease
- Conditions
- Hepatic Impairment, Cirrhosis, Cholestatic Liver Disease
- Trial name
- NCT05045482
- Testing
- Saroglitazar Magnesium 1 mg, Saroglitazar Magnesium 2 mg
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Zydus Therapeutics Inc.
Hepatitis C, Chronic
Noninvasive Evaluation of Hepatic Fibrosis in Chronic Hepatitis C
Chronic viral hepatitis C is a frequent liver disease. It is associated with variable degree of hepatic fibrosis. To date, liver histology is still regarded as the gold standard to detect, diagnose and quantify liver fibrosis.
- Trial name
- NCT00399815
- Where
- Belgium
- Volunteers
- 40 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Liver Diseases, Liver Cirrhosis
Sepsis, Endothelial Function, and Lipids in Critically Ill Patients With Liver Failure (the SELLIFA Study)
The purpose of the study is to determine the role of new biomarkers in the diagnosis of sepsis in critically-ill patients with liver failure and to correlate the prognosis of these patients with parameters of endothelial function…
- Conditions
- Liver Diseases, Liver Cirrhosis, Sepsis, Critical Illness
- Trial name
- SELLIFA (NCT00488917)
- Where
- Belgium
- Volunteers
- 167 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Liver Fat, Liver Fibrosis
Effect of Erugliflozin On Liver Fat, Liver Fibrosis and Glycemic Control in Type II DM Patients With NASH/NAFLD
Open-label, prospective, single-arm, multicenter study to determine effects of Ertugliflozin on liver fat, liver fibrosis \& glycemic control in subjects with Type 2 Diabetes Mellitus (T2DM) with Non-Alcoholic Fatty Liver Disease…
- Conditions
- Liver Fat, Liver Fibrosis, Glycemic Control, Body Weight Changes
- Trial name
- Ertu-NASH (NCT05644717)
- Testing
- Ertugliflozin 5 mg, 15mg
- Where
- Pakistan
- Volunteers
- 164 people
- Sponsor
- Getz Pharma